Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study

@article{Caspi2001PindololAI,
  title={Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study},
  author={N. Caspi and Ilan Modai and Peretz Barak and A. Waisbourd and H. Zbarsky and Shmuel Hirschmann and Michael S. Ritsner},
  journal={International Clinical Psychopharmacology},
  year={2001},
  volume={16},
  pages={111-115}
}
Treatment of aggression in schizophrenic patients is a major challenge. We sought to examine the efficacy of augmentation of antipsychotic treatment with pindolol in the amelioration of aggression. Thirty male inpatients meeting DSM-IV criteria for schizophrenia, aged 20-65 years involved in four or more aggressive incidents in the two previous months, were enrolled in a double-blind crossover study. Aggression was evaluated per incident, with the Overt Aggression Scale (OAS). Positive and… 
Fluvoxamine as an adjunctive agent in schizophrenia.
  • H. Silver
  • Psychology, Medicine
    CNS drug reviews
  • 2001
TLDR
The balance of available evidence indicates that fluvoxamine can improve primary negative symptoms in chronic schizophrenia patients treated with typical antipsychotics and suggests that it may also do so in some patients treating with clozapine, and this combination is generally safe and well tolerated.
Treatment of acute agitation in psychotic disorders.
TLDR
Evidence suggests that second-generation antipsychotics should be among the first-line choices in the treatment of agitation in acute psychosis.
Trials assessing parmacotherapeutic management of aggression in psychiatric patients: comparability with clinical practice.
TLDR
The low comparability of patients included in RCTs with those seen in clinical practice may decrease the generalizability of the findings form R CTs to clinical practice.
Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review.
TLDR
Paliperidone-extended release currently appears to be the agent for the management of hostility among inpatients with SSDs for which there is the strongest evidence of efficacy.
Treatment-refractory schizophrenia: what is it and what has been done about it?
TLDR
There has been a veritable explosion of research conducted for interventions that may be advantageous for the management of treatment-refractory schizophrenia, and research being done with antidepressant medications and with agents that impact on the glutamate receptor holds the greatest promise at this time.
The Psychopharmacology of Aggressive Behavior: A Translational Approach Part 1 Neurobiology
TLDR
The neurobiological mechanism of aggression is important to understand the rationale for using atypical antipsychotics, anticonvulsants, and lithium in treating aggressive behavior, and further research is necessary to establish how these neurotransmitter systems interact with brain circuits to control aggressive behavior at the intracellular level.
Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: A systematic review.
TLDR
Weak evidence for antiaggressive effects of antipsychotics, anti-depressants, anticonvulsants, and beta-adrenergic-blocking drugs was found.
The Psychopharmacology of Aggressive Behavior: A Translational Approach Part 2 Clinical Studies Using Atypical Antipsychotics, Anticonvulsants, and Lithium
TLDR
A critical review of all clinical trials using atypical antipsychotics, anticonvulsants, and lithium shows that a multifunctional combined therapy, targeting different receptors, seems to be the best strategy for treating aggressive behavior.
Beta-blocker supplementation of standard drug treatment for schizophrenia.
TLDR
Existing data on beta-blockers as adjunctive medication to antipsychotics for those with schizophrenia should be collected and re-analysed in order to allow confident conclusions about the effect of this treatment or the need for further trials.
The psychopharmacology of violence: making sensible decisions
TLDR
Short-acting intramuscular formulations of second-generation antipsychotics have become available and provide a means to induce calm with a substantially lower risk of acute dystonia or akathisia compared with haloperidol and new alternative formulations that avoid injections include inhalation and sublingual administration.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.
TLDR
Nadolol is of significant benefit in the treatment of aggression in chronic psychiatric inpatients and does penetrate the brain over time, but the success of a drug whose primary locus of action is peripheral may implicate a bimodal mechanism of action.
A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients.
TLDR
A controlled 3-week study of adjunctive use of nadolol, 80 to 120 mg per day, vs. placebo for the management of violent psychiatric patients finds the antiaggressive effects may be associated with sympathetic nervous system feedback mechanisms.
Can aggressive behavior in humans be modified by beta blockers?
  • J. Volavka
  • Psychology, Medicine
    Postgraduate medicine
  • 1988
TLDR
A review of several studies in which both old and young aggressive patients with various organic brain disorders received propranolol showed that aggressive behavior was reduced in 75 (86%) of 87 patients, encouraging because none of the patients had responded to earlier drug treatment.
Serotonergic function in aggressive and nonaggressive boys with attention deficit hyperactivity disorder.
TLDR
These data suggest that aggressive and nonaggressive children with attention deficit hyperactivity disorder differ in central 5-HT functioning, and the aggressive group had a significantly greater prolactin response to the fenfluramine challenge.
Serotonin uptake by platelets of suicidal and aggressive adolescent psychiatric inpatients.
TLDR
It is noteworthy that the lowest Vmax values of SPU were found in the patients of the affective group as compared to values of the three other diagnostic groups, similar to those concerning unipolar depressive adults.
The positive and negative syndrome scale (PANSS) for schizophrenia.
TLDR
Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes.
The authors successfully treated four patients who had irreversible CNS lesions and socially disabling aggressiveness and outbursts of rage, which had not been affected by high doses of major
Impulsive aggression and central serotonergic system function in humans: an example of a dimensional brain‐behavior relationship
  • E. Coccaro
  • Psychology, Biology
    International clinical psychopharmacology
  • 1992
TLDR
The results of these studies suggest that reduced overall central 5‐HT function in the limbic‐hypothalamic system is associated with suicidal and/or impulsive aggressive behaviors in patients with major mood and/ or personality disorders and that diminished 5-HT post‐synaptic receptor function in this brain region may be an important biological correlate of these behaviors.
The current state of psychiatry in the treatment of violent patients.
  • K. Tardiff
  • Psychology, Medicine
    Archives of general psychiatry
  • 1992
TLDR
The proper evaluation of violent patients is described and a model for the short-term potential of violent behavior is proposed and carbamazepine, propranolol hydrochloride, and lithium carbonate may be effective in diminishing violence.
Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia.
TLDR
The authors conducted a chart review to determine the effect of beta blockers on chronic assaultiveness in seven patients with chronic schizophrenia and four of the patients showed a greater than 70% decrease in actual assaults.
...
...